Table 5.
Adjusted comparison of neurobiological measurements between changes from baseline at 12 weeks after intervention in patients with mild AD (n = 16).
| Control group (n = 7) | Intervention group (n = 9) | Between-group difference (95%CI)a | P-value | |||
|---|---|---|---|---|---|---|
| Baseline | Change from baseline at 12 weeks | Baseline | Change from baseline at 12 weeks | |||
| Aβ-40 (pg/ml) | 212.0 (55.9) | −29.0 (43.5) | 219.4 (49.1) | −25.2 (35.7) | −1.2 (−47.0, 44.6) | 0.954 |
| Aβ-42 (pg/ml) | 40.6 (5.2) | 5.9 (10.5) | 57.9 (30.3) | −3.8 (31.0) | −8.9 (−38.9, 21.2) | 0.531 |
| Aβ42/Aβ40 | 0.20 (0.02) | 0.07 (0.09) | 0.26 (0.10) | 0.03 (0.16) | −0.03 (−0.2, 0.1) | 0.696 |
| BDNF (ng/ml) | 137.9 (29.1) | −23.5 (25.5) | 120.1 (25.8) | 29.9 (33.4) | 50.5 (13.9, 87.0) | 0.011 |
| IGF-1 (ng/ml) | 10.0 (1.6) | −0.03 (3.32) | 14.2 (8.2) | −1.5 (8.5) | −1.2 (−9.3,6.9) | 0.752 |
| TNF-a (pg/ml) | 3.8 (1.1) | 0.8 (0.3) | 3.8 (0.6) | 0.3 (0.4) | −0.4 (−0.9, 0.02) | 0.060 |
| IL-6 (pg/ml) | 2.3 (0.7) | 1.2 (0.7) | 2.4 (0.1) | 0.7 (0.7) | −0.5 (−1.3, 0.4) | 0.243 |
| sTREM-2 (pg/ml) | 9.7 (1.9) | 0.2 (4.6) | 18.0 (12.7) | −6.1 (13.0) | −6.4 (−18.9, 6.2) | 0.291 |
a
Controlling for age and sex.
Aβ-40, amyloid β-protein-40; BDNF, brain-derived neurotrophic factor; IGF-1, insulin-like growth factor-1; TNF-α, tumor necrosis factor-alpha; IL-6, Interleukin-6; sTREM2, soluble trigger receptor expressed on myeloid cells 2.